BPC 157 Dosing (Common Protocols), Oral Subcutaneous, 500 mcg daily, Duration: 6 weeks, Intramuscular Peritendinous, 1 mg daily, Duration: 6 weeks, Note:, Not approved by FDA or Wolff Parkinson White Syndrome The Cardiology Advisor Modulatory effects of BPC 157 on vasomotor tone and the activation of Src Caveolin 1 endothelial nitric oxide synthase pathway Scientific Reports What Is BPC 157? A Medical Clinic's Guide to the Body Protective Peptide, Its Uses, and What It Actually Does Perfect B